Literature DB >> 16857420

Experimental methods to study human transplacental exposure to genotoxic agents.

Kirsi Vähäkangas1, Päivi Myllynen.   

Abstract

Human placenta differs more than any other organ between species. This is the primary reason to develop models utilizing human tissue to study placental functions. There are no major ethical restrictions using human placenta for scientific studies. Also, the size of human placenta enables a great number of different parameters to be studied in one placenta. The most important cell types considering transplacental transfer, are the trophoblasts differentiating into syncytiotrophoblasts facing maternal circulation, and endothelial cells of fetal vessels. Primary trophoblasts are difficult to culture and do not grow in monolayer thus inhibiting studies on the polarized functions of transport. Several cell lines originating from trophoblasts have been developed, of which BeWo cells seem most useful for transport studies, because they grow in a tight monolayer. Placental tissue can also be retained as explant cultures, although the trophoblast viability is very restricted despite of culture conditions. Cotyledons of human placenta can be retained viable in an isolated organ perfusion. Perfused placental tissue stays viable longer than placental tissue in tissue culture. Although human placental perfusion is the most tedious experimental method to study placental functions, there are several good reasons to develop it further: transplacental transfer and molecular mechanisms of genotoxic compounds can be studied. Placental perfusion is the only experimental method that retains fully the structure of placenta for polarized transport. Furthermore, perfusion of placentas from mothers, who smoke, use illegal drugs or have a disease, allows studies on the impact of such factors on fetal exposure to genotoxic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857420     DOI: 10.1016/j.mrgentox.2006.02.014

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  11 in total

1.  Ex vivo perfusion of mid-to-late-gestation mouse placenta for maternal-fetal interaction studies during pregnancy.

Authors:  Nick Goeden; Alexandre Bonnin
Journal:  Nat Protoc       Date:  2012-12-13       Impact factor: 13.491

2.  Placental transfer of the polybrominated diphenyl ethers BDE-47, BDE-99 and BDE-209 in a human placenta perfusion system: an experimental study.

Authors:  Marie Frederiksen; Katrin Vorkamp; Line Mathiesen; Tina Mose; Lisbeth E Knudsen
Journal:  Environ Health       Date:  2010-07-05       Impact factor: 5.984

3.  Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Authors:  C Vinot; L Gavard; J M Tréluyer; S Manceau; E Courbon; J M Scherrmann; X Declèves; D Duro; G Peytavin; L Mandelbrot; C Giraud
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  Prediction of human fetal-maternal blood concentration ratio of chemicals.

Authors:  Chia-Chi Wang; Pinpin Lin; Che-Yu Chou; Shan-Shan Wang; Chun-Wei Tung
Journal:  PeerJ       Date:  2020-07-21       Impact factor: 2.984

Review 5.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

6.  The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models.

Authors:  Adelina Balan; Irit Szaingurten-Solodkin; Shani S Swissa; Valeria Feinshtein; Mahmoud Huleihel; Gershon Holcberg; Doron Dukler; Ofer Beharier
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

7.  Magnetic Nanoparticles Interact and Pass an In Vitro Co-Culture Blood-Placenta Barrier Model.

Authors:  Elena K Müller; Christine Gräfe; Frank Wiekhorst; Christian Bergemann; Andreas Weidner; Silvio Dutz; Joachim H Clement
Journal:  Nanomaterials (Basel)       Date:  2018-02-14       Impact factor: 5.076

8.  Maternal-Fetal Cancer Risk Assessment of Ochratoxin A during Pregnancy.

Authors:  Chit Shing Jackson Woo; Hani El-Nezami
Journal:  Toxins (Basel)       Date:  2016-03-23       Impact factor: 4.546

Review 9.  [Emerging viral infectious diseases and pregnancy].

Authors:  P-F Ceccaldi; P Longuet; L Mandelbrot
Journal:  Gynecol Obstet Fertil       Date:  2007-03-26

10.  Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV.

Authors:  Ahizechukwu C Eke; Adeniyi Olagunju; Brookie M Best; Mark Mirochnick; Jeremiah D Momper; Elaine Abrams; Martina Penazzato; Tim R Cressey; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.